(Q46799049)

English

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

author name string

Christiansen DH

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

Andersen MK

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

Desta F

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

Pedersen-Bjergaard J

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

19

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

12

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

2232-2240

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404009

0 references

Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Genetics of myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

BRAF mutations in acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

A critical function for B-Raf at multiple stages of myelopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

21 January 2018

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation of BRAF is uncommon in AML FAB type M1 and M2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

ras Oncogene Activation and Occupational Exposures in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational specificity of alkylating agents and the influence of DNA repair

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404009

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2404009

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16281072

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46799049&oldid=2132738612"